Samsung Biologics Revenue vs. Return On Equity
| 207940 Stock | 934,000 2,000 0.21% |
For Samsung Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Samsung Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Samsung Biologics Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Samsung Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Samsung Biologics Co over time as well as its relative position and ranking within its peers.
Samsung |
Samsung Biologics Return On Equity vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Samsung Biologics's current stock value. Our valuation model uses many indicators to compare Samsung Biologics value to that of its competitors to determine the firm's financial worth. Samsung Biologics Co is the top company in revenue category among its peers. It also is number one stock in return on equity category among its peers . The ratio of Revenue to Return On Equity for Samsung Biologics Co is about Huge . Comparative valuation analysis is a catch-all model that can be used if you cannot value Samsung Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Samsung Biologics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Samsung Revenue vs. Competition
Samsung Biologics Co is the top company in revenue category among its peers. Market size based on revenue of Biotechnology industry is presently estimated at about 2.95 Trillion. Samsung Biologics totals roughly 1.57 Trillion in revenue claiming about 53% of stocks in Biotechnology industry.
Samsung Return On Equity vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Samsung Biologics |
| = | 1.57 T |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Samsung Biologics |
| = | 0.0751 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Samsung Return On Equity Comparison
Samsung Biologics is currently under evaluation in return on equity category among its peers.
Samsung Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Samsung Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Samsung Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Samsung Biologics' important profitability drivers and their relationship over time.
Use Samsung Biologics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Samsung Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Samsung Biologics will appreciate offsetting losses from the drop in the long position's value.Samsung Biologics Pair Trading
Samsung Biologics Co Pair Trading Analysis
The ability to find closely correlated positions to Samsung Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Samsung Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Samsung Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Samsung Biologics Co to buy it.
The correlation of Samsung Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Samsung Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Samsung Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Samsung Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Samsung Biologics position
In addition to having Samsung Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Raw Materials Thematic Idea Now
Raw Materials
Companies that are involved with the development and processing of raw materials such as silver or forestry. The Raw Materials theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Raw Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Samsung Stock
To fully project Samsung Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Samsung Biologics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Samsung Biologics' income statement, its balance sheet, and the statement of cash flows.